Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML)
- Conditions
- Leukemia, Myelocytic, Acute
- Interventions
- Other: Autologous peripheral blood stem cell transplantation.Other: Allogeneic matched related or unrelated donor transplant.Other: CD34+ selection.Other: Mylotarg purging before autologous PBSC transplantation
- First Posted Date
- 2012-11-08
- Last Posted Date
- 2012-11-08
- Target Recruit Count
- 862
- Registration Number
- NCT01723657
- Locations
- 🇪🇸
Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸ICO Hospital Universitari de Bellvitge, L'Hospitalet del Llobregat, Barcelona, Spain
🇪🇸Hospital A Coruña, A Coruña, Coruña, Spain
Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML）
- Conditions
- MDSAML
- Interventions
- Drug: Granulocyte colony-stimulating factorOther: HLA haploidentical mononuclear cells infusion
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 29
- Registration Number
- NCT01690507
- Locations
- 🇨🇳
Navy General Hospital, Beijing, Beijing, China
🇨🇳Chinese PLA General Hospital, Beijing, China
AML-MDS Novel Prognostic Tests Clinical Study
- Conditions
- Myelodysplastic Syndrome (MDS)Acute Myeloid Leukemia (AML)
- First Posted Date
- 2012-09-14
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Nova Scotia Health Authority
- Target Recruit Count
- 11
- Registration Number
- NCT01685619
- Locations
- 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦Vancouver General Hospital, Vancouver, British Columbia, Canada
🇨🇦CancerCare Manitoba, Winnipeg, Manitoba, Canada
Phase I Study of Milatuzumab for Graft Versus Host Disease
- Conditions
- GVHD (Acute or Chronic)Multiple Myeloma (MM)Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL)Myelodysplastic SyndromeNon-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell)Acute Myeloid or Lymphoblastic Leukemia (AML or ALL)Chronic Myelogenous Leukemia (CML)
- Interventions
- First Posted Date
- 2012-08-13
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 12
- Registration Number
- NCT01663766
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2012-08-10
- Last Posted Date
- 2018-07-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 19
- Registration Number
- NCT01662505
- Locations
- 🇯🇵
Boehringer Ingelheim Investigational Site, Yoshida-gun, Fukui, Japan
Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
- Conditions
- NeutropeniaAcute Myeloid Leukemia (AML)Myeldysplastic Syndrome (MDS)Chronic Myelomonocytic LeukemiaBone Marrow Diseases
- First Posted Date
- 2012-06-27
- Last Posted Date
- 2019-12-17
- Target Recruit Count
- 4
- Registration Number
- NCT01629082
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients
- Conditions
- Acute Myeloid Leukemia (AML)Myelodysplastic Syndromes (MDS)Chronic Myelomonocytic Leukemia (CMML)
- Interventions
- First Posted Date
- 2012-06-07
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 10
- Registration Number
- NCT01613976
- Locations
- 🇯🇵
Novartis Investigative Site, Kyoto, Japan
Prospective Study on Severe Infections on Acute Myeloid Leukemia (AML) Patients
- Conditions
- AMLAdult
- First Posted Date
- 2012-04-04
- Last Posted Date
- 2022-10-12
- Target Recruit Count
- 144
- Registration Number
- NCT01570465
- Locations
- 🇮🇹
U.O. di Medicina Interna - ASUR Marche 8 - Ospedale Civile, Civitanova Marche, Ancona, Italy
🇮🇹S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
🇮🇹Azienda Ospedaliera - Nuovo Ospedale "Torrette", Ancona, Italy
The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).
- Conditions
- Myelodysplastic SyndromeAcute Myelogenous Leukemia
- Interventions
- First Posted Date
- 2012-03-16
- Last Posted Date
- 2012-03-16
- Lead Sponsor
- Nordic MDS Group
- Target Recruit Count
- 72
- Registration Number
- NCT01556477
- Locations
- 🇸🇪
Lars Möllgård, Stockholm, Sweden
Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia With 11q23-abnormality in Relapse
- Interventions
- First Posted Date
- 2012-03-09
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Steven E. Coutre
- Target Recruit Count
- 23
- Registration Number
- NCT01550224
- Locations
- 🇺🇸
Stanford University Medical Center, Stanford, California, United States